Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Files An 8-K Other Events
Item 8.01
| Other Events |
On April 4, 2017, Creative Medical Technology Holdings, Inc. (the
Company) issued a press release announcing the
filing of a patent application covering the use of its AmnioStem
Universal Donor stem cell product as a treatment of radiation
toxicity.
The press release, furnished as Exhibit 99.1 to this Form 8-K,
may contain forward-looking statements. Such forward-looking
statements are based on information presently available to the
registrants management and are current only as of the date made.
Actual results could also differ materially from those
anticipated as a result of a number of factors, including, but
not limited to, those discussed in the registrants Annual Report
on Form 10-K for the year ended December 31, 2016, and subsequent
reports filed by the Company with the Commission. For those
reasons, undue reliance should not be placed on any
forward-looking statement. The Company assumes no duty or
obligation to update or revise any forward-looking statement,
although it may do so from time to time as management believes is
warranted or as may be required by applicable securities law. Any
such updates or revisions may be made by the registrant by filing
reports with the Commission, through the issuance of press
releases or by other methods of public disclosure.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated April 4, 2017 |
About Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ)
Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc., is a clinical-stage company. The Company conducts its business operations primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT). The Company is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility, miscarriages and related issues. CMT focuses on completing the testing of its erectile dysfunction (ED) treatment and, if warranted, marketing treatment kits under the name Caverstem to physicians for use with their patients suffering from ED. CMT also intends to test and, if warranted, market licensed stem cell products under its infertility technology license. Procedures for use of the Company’s ED stem cell treatment consist of a one-hour out-patient visit in a physician’s office. The physician would harvest a patient’s bone marrow from the hip using local anesthetic and separate the stem cells using a cell separator. Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Recent Trading Information
Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) closed its last trading session 00.000 at 0.510 with shares trading hands.
